INO Stock News: Inovio Pharmaceuticals Inc. looks offered near $29.00

  • Inovio Pharmaceuticals Inc. (NASDAQ: INO) recedes from tops near $34.00.
  • NASDAQ: INO plans to start the Phase 2/3 in the next couple of months.

Shares of Inovio Pharmaceuticals (NASDAQ: INO) have opened Tuesday’s session with strong losses and are partially fading Monday’s sharp advance to the boundaries of the $34.00 mark, or fresh YTD highs.

NASDAQ: INO recently announced that it will start its studies of Phase 2 and 3 over the summer, all following recent positive news that its Phase 1 study showed that all of the participants in the clinical trial of its coronavirus vaccine candidate was well tolerated.

Investors, however, appear somewhat disappointed on Tuesday after the pharmaceutical company did not disclosure the results of the participants’ antibody response.

On the broader scenario, the coronavirus pandemic is far from over in the US, where many states continue to report record cases of infected cases, all amidst the ongoing efforts to re-open the economic activity and to return to some sort of normality.

INO Stock Quote

As of writing and following the opening bell in Wall St., NASDAQ: INO is down 6.8% at $29.53 and faces the next support at $26.06 (low Jun.30) seconded by $14.21 (55-day SMA) and finally $10.73 (100-day SMA). On the flip side, the initial hurdle is located at £33.79 (2020 high Jun.26).

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

FXStreet Trading Signals now available!

Access to real-time signals, community and guidance now!

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD bounces after upbeat COVID-19 cure news

EUR/USD is trading above 1.13, rebounding from the lows. Gilead reported that its drug Remdesevir substantially reduces mortality among COVID-19 patients. The news boosted stocks and weighed on the dollar. US coronavirus statistics are due out.


GBP/USD recaptures 1.26 as the market mood improves

GBP/USD is trading above 1.26 as the market mood improves and the safe-haven dollar retreats. Investors are shrugging off Brexit concerns and focusing on hopes to cure coronavirus. US COVID-19 statistics are due out.


XAU/USD consolidates daily gains above $1,800

After advancing to its highest level since September of 2011 at $1,818 on Wednesday, the XAU/USD pair staged a correction and briefly dropped below $1,800 on Thursday.

Gold News

Cryptocurrencies: War for dominance hit the bedrock of the market

Bitcoin tried to regain market share and activated sales in the Altcoin segment. BTC/USD, ETH/USD and XRP/USD are looking for supports and a rebound to push them to new elative highs. The current compression on the XRP/USD chart could trigger an exploding movement.

Read more

WTI once again breaks $40 per barrel after trading lower in early EU trade

There has been quite the bounce in WTI since the EU session after some strong selling pressure during Thursday and overnight. Once again on Friday's session, the price has taken the USD 40 per barrel handle. 

Oil News